Sclerotherapy for the management of rectal prolapse in children by Dolejs, Scott C. et al.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Sclerotherapy for the Management of Rectal Prolapse in Children 
AUTHORS: Scott C. Dolejs MD1, Justin Sheplock1, Robert J. Vandewalle MD1, Mathew P. 
Landman MD MPH1, Frederick J. Rescorla MD 1 
AFFILIATION: 
1 Indiana University School of Medicine, Division of Pediatric Surgery 
CORRESPONDING AUTHOR: 
 Frederick J. Rescorla MD 
705 Riley Hospital Dr #2500 
Pediatric Surgery 
Indianapolis, IN 46202 
Telephone: 317-274-4682 
Fax: 317-274-4491 
Current E-mail: frescorl@iupui.edu 
DISCLAIMERS: Dr.’s Dolejs, Sheplock, Vandewalle, Landman, and Rescorla have no conflicts 
of interest to disclose. 
FUNDING: There is no funding for this paper. 
AUTHOR CONTRIBUTION:  
Study Conception and Design: Scott Dolejs, Justin Sheplock, Frederick Rescorla 
Data Acquisition: Scott Dolejs, Frederick Rescorla, Justin Sheplock 
Analysis and Data Interpretation: Scott Dolejs, Matthew P. Landman, Frederick Rescorla 
Drafting of the Manuscript: Scott Dolejs, Justin Sheplock, Robert Vandewalle 
Critical Revision: Scott Dolejs, Justin Sheplock, Robert Vandewalle, Matthew P. Landman, 
Frederick Rescorla 
RUNNING TITLE: Sclerotherapy for rectal prolapse 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Dolejs, S. C., Sheplock, J., Vandewalle, R. J., Landman, M. P., & Rescorla, F. J. (2017). Sclerotherapy for the Management of 
Rectal Prolapse in Children. Journal of Pediatric Surgery. https://doi.org/10.1016/j.jpedsurg.2017.10.015
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
ABSTRACT: 
PURPOSE: Rectal prolapse is a commonly occurring and usually self-limited process in 
children. Surgical management is indicated for failures of conservative management. However, 
the optimal approach is unknown. The purpose of this study is to determine the efficacy of 
sclerotherapy for the management of rectal prolapse. 
METHODS: This was a retrospective review of children <18 years with rectal prolapse who 
underwent sclerotherapy, predominantly with peanut oil (91%), between 1998 and 2015. 
Patients with imperforate anus or cloaca abnormalities, Hirschprung disease, or prior pull-
through procedures were excluded. 
RESULTS: Fifty-seven patients were included with a median age of 4.9 years (interquartile 
range (IQR) 3.2-9.2) and median follow-up of 52 months (IQR 8-91). Twenty patients (n=20/57; 
35%) recurred at a median of 1.6 months (IQR 0.8-3.6). Only 3 patients experienced recurrence 
after 4 months. Nine of the patients who recurred (n=9/20; 45%) were re-treated with 
sclerotherapy. This was successful in 5 patients (n=5/9; 56%). Two patients (n=2/20; 10%) 
experienced a mucosal recurrence which resolved with conservative management. Forty-four 
patients were thus cured with sclerotherapy alone (n=44/57; 77%). No patients undergoing 
sclerotherapy had an adverse event. Thirteen patients (n=13/20; 65%) underwent rectopexy 
after failing at least one treatment of sclerotherapy. Three of these patients (n=3/13; 23%) 
recurred following rectopexy and required an additional operation. 
CONCLUSIONS: Injection sclerotherapy for children with rectal prolapse resulted in a durable 
cure of prolapse in most children. Patients who recur following sclerotherapy tend to recur within 
4 months. Another attempt at sclerotherapy following recurrence is reasonable and was 
successful half of the time. Sclerotherapy should be the preferred initial treatment for rectal 
prolapse in children and for the initial treatment of recurrence. 
KEYWORDS: Rectal prolapse; Sclerotherapy 
LEVEL OF EVIDENCE: Level IV 
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TYPE OF STUDY: Treatment Study 
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INTRODUCTION: 
 Rectal prolapse is a relatively common condition in children that typically occurs before 
the year of four, around the time toilet training begins [1-4]. It is most frequently idiopathic and 
self-limited and resolves with improved toileting habits and stool softeners within one year in the 
majority of patients [1-6]. If prolapse persists despite optimal management, various strategies 
exist for treatment. These include injection sclerotherapy [4-17], encircling of the anus, also 
known as the Thiersch operation [10, 18], abdominal operations [3, 13, 19, 20], and perineal 
operations [10, 21]. Given the varied approaches, no one technique currently predominates 
thereby creating a wide heterogeneity in practice patterns.  
Sclerotherapy has several potential advantages including its minimally invasive nature 
and low complication profile [4]. We seek to determine the success of injection sclerotherapy in 
patients with rectal prolapse who failed conservative management in a large, tertiary academic 
center. We also aim to characterize factors associated with failure of sclerotherapy to determine 
if there are patients who may benefit from initial operative management. 
MATERIALS AND METHODS: 
This is a single institution retrospective review of patients less than 18 years old who 
underwent injection sclerotherapy for rectal prolapse between 1998 and 2015. Patients with 
imperforate anus or cloaca abnormalities, Hirschprung’s disease, or prior pull-through 
procedures were excluded. Additionally, two patients who underwent primary rectopexy were 
excluded. Appropriate institutional review board approval was obtained prior to initiating the 
study. 
 Patients with rectal prolapse were treated via a standard pathway. This standard 
pathway included initial medical management with fiber supplementation in all patients. If 
patients had constipation, they were treated with laxatives. Behavior modification was used in all 
patients which included minimizing time on the toilet and avoiding. If medical management failed 
to resolve the prolapse in 1-3 months, patients were considered for injection sclerotherapy. The 
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surgery was performed by multiple surgeons at a single hospital. Pre-operative preparation 
involved decompression of the rectum with an enema or suppository with intra-operative 
irrigation as needed. Patients were placed in the lithotomy position under general anesthesia. A 
digital rectal examination was performed to rule out the presence of rectal polyps or other 
abnormalities. The majority of patients received 5% phenol in peanut oil as the sclerosing agent, 
which was compounded by the pharmacy department and then dry-heat sterilized with a batch 
sent to microbiology for sterility testing prior to release of the dose for patient use. Alternative 
sclerosant agents included 5% phenol in almond oil or concentrated dextrose solutions (25% or 
higher) and were utilized based on patient allergy profiles. The agent was administered via 
direct injection into the submucosal tissue, beginning at the dentate line and extending 
approximately 8 cm proximally up the rectal wall. This was performed in 4-quadrants around the 
rectum. 
 Statistical analysis was performed with SAS version 9.4 (SAS Institute Inc, Cary, NC). 
Continuous variables were not normally distributed; thus, median values with interquartile range 
(IQR) are displayed. Univariate analysis was conducted with Chi-square, Fisher’s exact test, or 
Wilcoxon-Rank Sum tests as appropriate. 
RESULTS: 
 Fifty-seven patients undergoing injection sclerotherapy were included for analysis. 
Patient demographics, operative characteristics, and post-operative results are given in Table 1. 
Patients were followed for a median of 52 months (IQR: 7.6-91.0 months). 
 Phenol in peanut oil was the predominant sclerosant used (n=51/57; 91%). Three 
patients with a peanut allergy underwent sclerotherapy with phenol in almond oil and two 
patients with nut allergies underwent sclerotherapy with concentrated dextrose solution. The 
median volume of sclerosant was 10 mL (IQR: 10-15 mL) and the median sclerosant volume 
per kg was 0.5 mL/kg (IQR: 0.3-0.8 mL/kg). Sclerotherapy was performed as an outpatient 
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procedure in all cases and none of the patients undergoing sclerotherapy experienced a post-
operative complication. 
 Recurrence occurred in 20 patients (n=20/57; 35%) (Figure 1). The majority of patients 
(n=17/20; 85%) experienced recurrence in the first four months after sclerotherapy. In two of the 
patients with recurrence (n=2/20; 10%), medical management of their constipation resulted in 
resolution of prolapse without further operative management. Nine patients (n=9/20; 45%) 
underwent repeated sclerotherapy. This was successful in five patients (n=5/9; 56%). Three 
patients were cured after 2 total rounds of sclerotherapy, one person was cured after 3 total 
rounds of sclerotherapy, and one person was cured after 4 total rounds of sclerotherapy, with 
treatment intervals from one months to several years. Thus, in total, sclerotherapy alone 
resulted in a durable cure of rectal prolapse in forty-four patients (n=44/57; 77%). Four patients 
who underwent repeated sclerotherapy (n=4/9; 44%) eventually required a rectopexy. One of 
these four patients required a sigmoidectomy and Hartmann pouch after failed rectopexy. Nine 
patients underwent rectopexy after one attempt at sclerotherapy. Two of these patients required 
another operation for rectal prolapse. This involved an excision of rectal procidentia with 
anastomosis via a perineal approach in one patient and a sigmoidectomy via abdominal 
approach in another patient. Thus, thirteen total patients (n=13/20; 65%) with recurrence 
following sclerotherapy underwent a rectopexy. Three of these patients (n=3/13; 23%) recurred 
and required another operative intervention. 
 In evaluating factors associated with recurrence, older age, higher weight, and 
sclerosant other than phenol in peanut oil were all significantly associated with recurrence (p-
value<0.05). All patients who used phenol in almond oil or dextrose solution experienced a 
recurrence. Two of the three patients with recurrence following phenol in almond oil 
sclerotherapy required rectopexy and the other patient was cured with repeated sclerotherapy. 
Both patients with recurrence after dextrose injection sclerotherapy were cured with repeated 
sclerotherapy. Higher sclerosant volume was associated with recurrence (p-value=0.02). 
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However, there was no association with sclerosant volume and recurrence after standardization 
patient weight (p-value=0.41). 
 In evaluating factors associated with eventual success of sclerotherapy or eventual 
requirement of operative management, similar factors to recurrence were associated with 
requirement for eventual operation, but the differences in groups are larger (Table 4). Patients 
who required operative management were 7.9 years older on average and 28 kg heavier on 
average. There was a patient who was 18 years old and another who weighed 71 kg whose 
rectal prolapse was cured with sclerotherapy alone. 
DISCUSSION: 
 In our single center retrospective review that spanned over 15 years, fifty-seven patients 
who underwent primary injection sclerotherapy for rectal prolapse were examined. This 
represents one of the largest series of injection sclerotherapy in the current literature. Our 
results demonstrate that the first sclerotherapy results in durable cure of prolapse in 68% of 
patients and repeat sclerotherapy will eventually result in a durable cure of prolapse in 77% of 
patients. This cure rate is similar to the current literature, in which injection sclerotherapy has 
been found to result in durable cure 70-95% of the time [4, 5, 8, 9, 11-13, 15, 16]. If a 
recurrence occurred, it most commonly occurred within the first four months, indicating that 
sclerotherapy also results in durable cure in the majority of our patients. Further, sclerotherapy 
was performed as an outpatient procedure in all cases and no complications occurred in 
patients who underwent sclerotherapy. While there have been reports of death following 
injection sclerotherapy due to phenol toxicity, the vast majority of reports on injection 
sclerotherapy have shown sclerotherapy is safe with minimal complications  [4, 5, 8, 9, 11-13, 
15, 16, 22]. One report noted an association of abscess formation with injection sclerotherapy 
with phenol in almond oil, and it may be that our process of dry-heat sterilization combined with 
batch culture prior to utilization in patients prevented this complication from occurring [15]. 
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Injection sclerotherapy represents a safe, minimally invasive, and efficacious treatment of rectal 
prolapse. 
 Despite its efficacy, thirteen patients eventually required an abdominal operation to treat 
their rectal prolapse. In our evaluation of factors associated with recurrence and eventual need 
for operative management, several significant factors were noted. First, in comparing different 
sclerosants, our results demonstrate that all patients with phenol in almond oil and dextrose 
experienced recurrence. Both patients with dextrose sclerotherapy resolved with repeated 
sclerotherapy, but two of the three patients with phenol in almond oil required operative 
management. Phenol in almond oil has been found to be an effective sclerosant compared to 
cow’s milk, 30% saline solution, 30% dextrose solution, and 70% ethyl alcohol solution [23]. In 
another study, phenol in almond oil was effective in all patients, but was associated with a 9% 
rate of abscess and mucosal sloughing in 27% [15]. In light of these studies and our study, 
phenol in peanut oil or concentrated dextrose should be the preferred sclerosant agent. In 
regards to volume, although there was not a statistically significant association, patients without 
recurrence had a median volume of 0.50 mL/kg of sclerosant compared with 0.38 mL/kg in 
patients who experienced a recurrence. Thus, a volume of 0.50 mL/kg of sclerosant divided 
over four quadrants appears a prudent volume to treat rectal prolapse. 
 Our study also highlights that older patients who weigh more are more likely to 
experience recurrence and eventually need an operation. This is congruent with prior studies 
that have investigated a relationship between age and recurrence following prolapse [13]. This 
has led other studies to recommend early definitive corrective surgery in older children (older 
than 5 years old) who do not respond to conservative measures or injection sclerotherapy [13]. 
However, our results also highlight that patients as old as 18 years old or who weigh as much 
as 71 kg were successfully treated with sclerotherapy. Thus, a trial of sclerotherapy and at least 
one additional sclerotherapy appear reasonable given the favorable complication profile of this 
technique. Further, even amongst the thirteen patients who underwent surgical repair, three 
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required an additional operation (n=3/13; 23%), indicating that surgery itself is not a guarantee 
of successful resolution of prolapse. 
 These findings need to be viewed in light of limitations inherent in this method of 
investigation. One important potential limitation is that it is unknown how many of these patients 
would have had resolution of their prolapse without any treatment. While all patients were given 
a trial of conservative measures, we cannot know how many of the patients who underwent 
operative intervention would have had resolution of their symptoms without operative 
intervention. Another important limitation is potential losses to follow-up. While we had a robust 
median follow-up of 52 months and were able to utilize a statewide database to see if patients 
were treated at other facilities, it is still possible there were recurrences that were not captured 
as a result of the retrospective nature of this study. Thus, this study may overestimate the 
effectiveness of injection sclerotherapy. Another limitation is low power and number of events. 
In particular, a multivariable analysis would be able to better define which factors are 
independently associated with recurrence. Unfortunately, with only twenty events of recurrence 
and only thirteen patients requiring operative management, we would only be able to include 
two factors into this analysis rendering this technique not particularly useful in our series.  
CONCLUSIONS: 
 Injection sclerotherapy is an effective treatment strategy for children with rectal prolapse. 
It should be the first-line treatment in patients who fail a trial of conservative management. 
Repeat injection sclerotherapy should be the favored approach for recurrence. In older and 
heavier patients, consideration for earlier operative intervention should be considered. However, 
even these patients can benefit from a trial of injection sclerotherapy with a repeated treatment 
should a recurrence occur. 
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Figure 1: Flowchart demonstrating the treatment pathway of patients with rectal prolapse 
recalcitrant to medical therapy who underwent primary sclerotherapy 
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Table 1: Pre-operative, operative, and post-operative characteristics of patients undergoing 
injection sclerotherapy for recalcitrant rectal prolapse 
 n (%) or Median (Interquartile 
Range) 
Pre-operative Characteristics:  
Gender (male, n (%)): 42 (73.7%) 
Age (yrs; median (IQR)): 4.9 (3.2-9.2) 
Weight (kg; median (IQR)): 20.0 (15.0-34.0) 
Length of Follow-up (months; median 
(IQR)): 
51.9 (7.6-91.0) 
  
Operative Characteristics:  
Sclerosant Used (n (%))*:  
     Peanut oil with phenol: 51 (91.1%) 
     Almond oil with phenol: 3 (5.4%) 
     Dextrose solution: 2 (3.6%) 
Sclerosant Volume (mL; median (IQR)): 10 (10-15) 
Sclerosant Volume/Weight (mL/kg; median 
(IQR)): 
0.47 (0.33-0.77) 
  
Post-operative Complications:  
Recurrence (n (%)): 20 (35.1%) 
Sclerotherapy first for Recurrence (n (%)): 9 (45.0%) 
Surgical Repair (n (%)): 13 (65.0%) 
Resolved without surgery (n (%)): 2 (10.0%) 
Length to Recurrence (months; median 
(IQR)): 
1.6 (0.8-3.6) 
 
*    The sclerosant used was not charted in one patient  
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Table 2: Pre-operative and operative factors associated with recurrence following primary 
sclerotherapy 
Pre-operative and Operative 
Factor 
No Recurrence 
(n=37) 
Recurrence 
(n=20) 
p-
value 
Gender (male, n (%)): 29 (78.4%) 13 (65.0%) 0.27 
Age (yrs; median (IQR)): 4.2 (3.0-5.9) 8.2 (4.8-13.4) <0.01 
Weight (kg; median (IQR)): 18.0 (14.5-21.5) 37.0 (23.0-53.0) <0.01 
Sclerosant Used (n (%))*:   <0.01 
     Peanut oil with phenol: 36 (100.0%) 15 (75.0%)  
     Almond oil with phenol: 0 (0.0) 3 (15.0%)  
     Dextrose solution: 0 (0.0) 2 (10.0%)  
Volume (mL; median (IQR)): 10.0 (9.0-12.5) 12.8 (10.0-18.5) 0.02 
Volume/Weight (mL/kg; median 
(IQR)): 
0.50 (0.37-0.77) 0.38 (0.29-0.78) 0.41 
 
*    The sclerosant used was not charted in one patient 
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Table 3: Pre-operative and operative factors associated with eventual need for operative 
management following primary injection sclerotherapy 
Pre-operative and 
Operative Factor 
Resolved with 
sclerotherapy alone 
 (n=44) 
Required operative 
management 
(n=13) 
p-value 
Gender (male, n (%)): 34 (81.0) 8 (61.5) 0.29 
Age (yrs; median 
(IQR)): 
4.6 (3.0-6.2) 12.5 (6.5-14.3) <0.01 
Weight (kg; median 
(IQR)): 
18.0 (15.0-23.0) 46.0 (29.0-70.0) <0.01 
Sclerosant Used (n 
(%))*: 
  0.18 
     Peanut oil with 
phenol: 
40 (93.0) 11 (84.6)  
     Almond oil with 
phenol: 
1 (2.3) 2 (15.4)  
     Dextrose solution: 2 (4.7) 0 (0.0)  
Volume (mL; median 
(IQR)): 
10.0 (9.5-12.8) 15.0 (10.0-20.0) 0.03 
Volume/Weight 
(mL/kg; median 
(IQR)): 
0.50 (0.38-0.77) 0.34 (0.23-0.49) 0.06 
 
*    The sclerosant used was not charted in one patient 
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SLEROTHERAPY FOR THE MANAGEMENT OF  
RECTAL PROLAPSE IN CHILDREN 
 Presented by Matthew Landman, Indianapolis IN 
 
CARLOS ______ (Knoxville, TN): Where specifically do you do your 
injections? The reason I am asking this question is that we also 
do it in four quadrants, but I had one patient who had transient 
loss of sensation, and I think it probably had to do with 
inflammation of the nerves around the area. This person became 
incontinent for about 2-3 weeks due to the loss of sensation, so 
we try to avoid the 3 and 9 o’clock positions for our 
injections. I wonder how you do it. 
 
MATTHEW LANDMAN: We start at the dentate line, hopefully that 
gets around the innervation of the sphincter muscle, and then go 
proximally 8 cm. We have found that there were no adverse events 
from these injections, so I think starting at the dentate line 
and going proximally may prevent that complication.  
 
ROBERT BAIRD (Montreal, QC): Nicely presented. We learned 
yesterday that there is considerable variability in practitioner 
decision and the interval between first presentation to go to 
sclerotherapy. Can you enlighten us on how you decided to take 
your children for sclerotherapy? What were your indications? 
 
MATTHEW LANDMAN: That’s sort of the crux. When is enough time 
for medical management? All the patients that presented to our 
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surgical clinic had essentially been maximally medically 
managed, and we didn’t really look through the times, and that’s 
kind of the next step in our process. From our standpoint, 
barring those patients who have difficult reductions or present 
to the emergency department frequently for reductions, that 
would be an indication for more urgent intervention. I think it 
is surgeon specific in our institution and there was no specific 
algorithm ____ the time, unfortunately.  
 
ROBERT BAIRD: I’d encourage you to drill down. 
 
MATTHEW LANDMAN: We will.  
 
RAMEN JAMSHIDI (Phoenix, AZ): Nice presentation on something 
where there’s a dearth of literature, but a useful technique. To 
piggyback on the last question, what time interval did you allow 
for resolution of recurrences before proceeding with the second 
treatment? 
 
MATTHEW LANDMAN: Based on this data and the practice, it’s going 
to be less than a couple of months. I think if you don’t have 
recurrence up front within that first two--month period, you can 
be a little bit more at ease about waiting longer. Within that 
first 1-2 months is a reasonable approach.  
